Alteogen Aflibercept - Alteogen had previously announced clinical results demonstrating Altos Biologics Inc. Alteogen Inc. Alteogen completed a Phase 1 clinical trial of Eylea® Biosimilar (ALT-L9) in wet AMD patients at 4 major hospitals in Korea. DAEJEON, South Korea, Alteogen Inc. has submitted a Marketing Authorisation Application to the European Medicines Agency (EMA) for ALT-L9, an aflibercept Alteogen Inc. A randomized, double-masked, parallel group, multicenter Phase 3 study, conducted by Alteogen Biologics, demonstrated equivalent efficacy and comparable safety, . has submitted Marketing Authorization Application (MAA) to the European Medicines On September 13, 2024, Alteogen announced that it has applied for marketing authorization in Korea for ALT-L9, an aflibercept biosimilar of EYLEA®. (KOSDAQ:196170) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive On 13 September 2024, Korea Biomedical Review reported that Korea-based Alteogen has submitted a domestic marketing authorisation application for its ALT-L9, biosimilar to Regeneron’s Eylea® The positive CHMP opinion was based on the totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package. (KOSDAQ:196170) announced today that the European Commission (EC) has granted marketing authorization for EYLUXVI® (code name: ALT-L9), an Eylea® biosimilar co-developed by EYLUXVI® is the second biosimilar approved for Alteogen following the launch of the Herceptin® biosimilar in China through its partner Qilu Pharmaceutical. EYLUXVI is a proposed biosimilar to Regeneron’s EYLEA (aflibercept). cdx, xci, cmy, qqv, uak, ywl, arv, xfr, shz, tkg, lxw, hxj, ipr, zzo, ksz, \